Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftriaxone-sulbactam for pediatric acute bacterial infection
CTR20132092Phase 4Active
- Sponsor
- Xiangbei Welman Pharmaceuticals
- Start
- Mar 2015
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ceftriaxone + sulbactam in There is no single canonical disease name for "acute bacterial infection" as it refers to a broad category of diseases rather than a specific condition., sponsored by Xiangbei Welman Pharmaceuticals. Started Mar 2015; status: active.
02
Drugs
ceftriaxone + sulbactam
03
Conditions
There is no single canonical disease name for "acute bacterial infection" as it refers to a broad category of diseases rather than a specific condition.
Beyond the preview
Go deeper on CTR20132092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132092.